Galectin Therapeutics
GALT
62 hedge funds and large institutions have $13.6M invested in Galectin Therapeutics in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 7 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
5% more capital invested
Capital invested by funds: $13M → $13.6M (+$656K)
0% more funds holding
Funds holding: 62 → 62 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
56% less call options, than puts
Call options by funds: $76K | Put options by funds: $171K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.61M |
| 2 |
AIG
American International Group
New York
|
+$578K |
| 3 |
D.E. Shaw & Co
New York
|
+$238K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$61.4K |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$59.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$418K |
| 2 |
Morgan Stanley
New York
|
-$287K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$195K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$138K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$135K |
GALT Hedge Fund Activity: Q1 2015 in Review
62 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2015, worth a combined $13.6M — up 5.1% from $13M a quarter earlier.
Fund positioning in GALT was balanced in Q1 2015: 7 funds opened new positions, 7 closed out, 20 added to existing stakes and 17 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.61M. The largest seller was Susquehanna International Group, cutting an estimated $418K.
- 62 institutional investors held Galectin Therapeutics (GALT) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $13.6M of Galectin Therapeutics stock for Q1 2015, up 5.1% quarter-over-quarter.
- 7 funds opened new Galectin Therapeutics positions in Q1 2015 and 7 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q1 2015 was Sphera Funds Management, an estimated $1.61M added.
- The largest Galectin Therapeutics seller in Q1 2015 was Susquehanna International Group, an estimated $418K sold.
Based on aggregated 13F filings for Q1 2015.